ELANA® Bypassing open heart surgery with Excimer Laser Assisted Non Occlusive Anastomosis (ELANA®)

Summary

We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with “keyhole” minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA® technology enables reproducible coronary artery bypass grafting (CABG) surgery
without the need of heart arrest and suturing, thus avoiding the need to open the patient’s chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA® reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA® will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of €7.5M funding (€2.5M grant, €5M equity) to finalise clinical validation and gain market approval.

Resources

Show all and search (1)

Unfold all

Fold all

More information & hyperlinks

Web resources:	https://cordis.europa.eu/project/id/190101904
Start date:	01-10-2022
End date:	30-09-2025
Total budget - Public funding:	3 614 062,50 Euro - 2 497 469,00 Euro

Cordis data

Original description

We will revolutionise the medical field by replacing expensive, invasive and high-risk open-heart surgery, with keyhole minimally invasive surgery (MIS) to treat coronary artery disease (CAD). Our ELANA technology enables reproducible coronary artery bypass grafting (CABG) surgery
without the need of heart arrest and suturing, thus avoiding the need to open the patients chest. This is realised with an innovative clip which circumvents the need of suturing of blood vessels altogether. By realising closed-chest CABG, ELANA reduces not only the risks associated with
traditional CABG, such as bleeding, stroke and wound infection, but also significantly shortens recovery times. As a result, ELANA will reduce direct healthcare costs of CABG procedures by over 50%. To critically de-risk our technological development and accelerate market entry to 2025, AMT
Medical seeks a total of 7.5M funding (2.5M grant, 5M equity) to finalise clinical validation and gain market approval.